CMS Open Payments · Program Year 2024
Hyperfine Operations, Inc.
Hyperfine Operations, Inc. reported $568,552.03 across General Payments, Research, and Ownership to 56 physicians and teaching hospitals across 76 transactions.
- $568.6K Above-median payer
- All-tracks total
- 76 Below-median volume
- Transactions
- 56 Below-median reach
- Recipients
- +$32.2K
- General Payments vs PY2023
Hyperfine Operations, Inc. reported $568,552.03 across all CMS Open Payments tracks (General + Research + Ownership) to 56 physicians and teaching hospitals in Program Year 2024 - ranking #732 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $52,350.05, averaging $10.2K per recipient.
How Hyperfine Operations, Inc.'s $568.6K all-tracks total breaks down
Hyperfine Operations, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
18/100
Total payments
F
15/100
Transaction volume
F
11/100
Physician reach
F
10/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer hyperfine-operations-inc Hyperfine Operations, Inc.
$568.6K · #732/1,925 · 0.0% industry · PY2024
- TOT $568.6K
- RANK #732
- SHARE 0.0%
- TXN 76
- RCP 56
- CAT 3
- GEN $52.4K
- ΔGEN +$32.2K
- TOP1 47.4%
- PY 2024
Volume peers
Nearest volume peer: Perfuze Limited ($568.2K)
Hyperfine Operations, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Hyperfine Operations, Inc.'s CMS-reported General Payments increased by $32.2K (+159.4%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: HYPERFINE OPERATIONS, INC.PY2023: HYPERFINE OPERATIONS, INC.PY2024: Hyperfine Operations, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $20,178.71
- PY2024
- $52,350.05
What the Data Shows for Hyperfine Operations, Inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Hyperfine Operations, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
The 3-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $44.4K, accounting for 84.9% of this company's General Payments and 33 transactions.
General Payment Breakdown by Type
"Consulting Fee" leads Hyperfine Operations, Inc.'s 3-category general-payment breakdown at $44.4K, 84.9% of the reported total.
How Hyperfine Operations, Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $44.4K | 33 | 84.9% |
| Travel and Lodging | $6.9K | 3 | 13.2% |
| Food and Beverage | $1.0K | 20 | 1.9% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $47,111.37 (90.0%) of $52,350.05 in this company's General Payments records across 24 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Hyperfine Operations, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Charles Truwit
$24,836.76 across 5 reported transactions
- 2
Jennifer Frabizzio
$6,625.00 across 12 reported transactions
- 3
Jude-Patrick Okafor
$5,924.61 across 7 reported transactions
- 4
Chetan Shah
$5,475.00 across 3 reported transactions
- 5
Judy M Chang
$4,250.00 across 6 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Hyperfine Operations, Inc.'s spend rank (#732 of 1,925, top 38% by spend) and concentration rank (#609 of 1,838, top 33% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Pramand LLC : $22.8K total payments, HHI 2763
- Cleerly, Inc. : $157.5K total payments, HHI 2760
- Biodynamik, Inc : $23.6K total payments, HHI 2759
- Blue Sky Bio, LLC : $314.2K total payments, HHI 2746
- BTG International, Inc. : $670.8K total payments, HHI 2745
- Carbofix Orthopedics Inc : $49.7K total payments, HHI 2743
- Hyperfine Operations, Inc. (this company) : $52.4K total payments, HHI 2743
- 3NT Medical : $11.0K total payments, HHI 2735
- Boehringer Ingelheim Pharma GmbH & Co.KG : $27.7K total payments, HHI 2733
- Carter Bloodcare : $22.6K total payments, HHI 2730
- Kyowa Kirin Services Ltd : $24.7K total payments, HHI 2718
- Dentsply Sirona Orthodontics Inc : $133.4K total payments, HHI 2714
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Hyperfine Operations, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Hyperfine Operations, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Hyperfine Operations, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Republic Spine
Expanding Innovations, Inc.
Zest Holdings, LLC
CTL Medical Corporation
Maxx Orthopedics, Inc.
Put this to use
Hyperfine Operations, Inc. ranks #732 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Hyperfine Operations, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.